Read time: 10 minutes
Welcome back to The Ruck Filter.
On Wednesday EQT agreed to take Qiagen private at €46.50 a share. In 2020 Thermo Fisher offered €43, needed two-thirds of the shares and got 47%. This time half the shares plus one is enough. On Friday Bloomberg reported that BASF has gone back to Evonik with about €24 a share, and this Wednesday Thyssenkrupp lists its materials unit. In Paris the ten-year yield touched 5.14%, the highest since 2002, and France now pays 48 basis points more than Italy to borrow for ten years. Brent closed at $116.72. On 14 October futures priced a 41.5% chance of a Fed hike this week. Now the figure is about 5%.
Three stories about thresholds, and about who has to say yes before a price holds. The first section covers three deals and ends with points to screen for. The second ends with a bond idea. The third is macro, so it is shorter. After that come the Insider Radar and a short check of last week’s list.
1. Signal vs. Noise: Three Deals, Three Gatekeepers 🗝️
The Noise: Private equity is back, and German takeover candidates are worth buying.
The Alpha: In each of this week’s three German deals the price depends on someone other than the ordinary shareholder. At Qiagen it is a threshold of 50% plus one share, with a tax cost for anyone who refuses. At Evonik it is a foundation whose board is mostly politicians. At TK Accelis it is a parent that keeps 51%. The gap between each share price and its offer shows how the market rates the gatekeeper.
The Filter: EQT, with the Abu Dhabi Investment Authority and CPP Investments, agreed on Wednesday to buy Qiagen for €46.50 a share in cash, 8.6% above the previous close and about €9.6 billion in total (Reuters). Both boards support the offer. It is a voluntary takeover offer under German law for a Dutch company, with a minimum acceptance of 50% of the shares plus one. After closing, an extraordinary general meeting is to approve further steps. Shareholders who haven’t tendered would then receive the offer price less applicable withholding taxes, and the listings in Frankfurt and New York would end. Closing is expected in mid-2027 (SEC filing). On the same evening Qiagen suspended its 2026 outlook and published preliminary third-quarter sales of $548 million. The price of $52.22 a share is about 22 times last year’s adjusted earnings per share of $2.38 (dpa-AFX).
The last attempt shows why the threshold matters. In 2020 Thermo Fisher raised its offer from €39 to €43 a share and lowered the minimum acceptance from 75% to 66.67%. Shareholders tendered 47.02%, and the offer lapsed (Analytica-World, The Pharma Letter). In January this year the stock came close to €48 on takeover talk and fell to about €27.50 in the summer. Bloomberg reported that KKR had also bid. No one has confirmed that (Börsen-Zeitung). On Friday Qiagen closed at €45.05, 3.2% below the offer (Börse Express). Spread over the roughly eight months to mid-2027, that is about 4.8% a year. A two-year Bund yields 3.03% (Trading Economics). The difference, about 1.8 points a year, is what the market charges for the risk that the deal fails.
At Evonik nothing is signed. BASF made a non-binding approach for all shares in late September at a reported €22.15, about €10.3 billion, which Evonik rejected as too low. On Friday Bloomberg reported a new figure of about €24, just over €11 billion. Neither company commented (dpa-AFX). Evonik closed at €21.26, up 2.7%. Before the first reports it traded at about €18. The RAG-Stiftung holds about 43%, and most of its 13 board members are politicians. The state government of North Rhine-Westphalia is against the deal. Economy minister Mona Neubaur: “damit ist klar, dass wir gegen diese Übernahme sind,” that makes it clear that the state is against it (Börse Express). BASF chief executive Markus Kamieth has promised to honour existing site agreements. If €24 is the outcome and about €18 the alternative, Friday’s price implies a little over even odds.
At €24 Evonik’s 466 million shares would be worth about €11.2 billion, and with €3.6 billion of net financial debt the business about €14.8 billion. That is roughly seven times the €2.0 to 2.2 billion of adjusted EBITDA Evonik expects this year. Part of this year’s profit is linked to the war. When Evonik raised its outlook in June, it cited supply problems at Asian competitors, and in August it pointed to higher margins in its C4 business, both tied to the conflict in the Middle East. In June it also expected business to weaken later in the year as global shipping stabilised after the Strait of Hormuz reopened (Evonik).
Thyssenkrupp’s materials unit, TK Accelis, starts trading in Frankfurt’s Prime Standard on Wednesday. Thyssenkrupp shareholders receive one share for every 20 they hold, and Thyssenkrupp keeps 51%. Most of the business is low-margin trading in steel and plastics. The higher-margin “Solutions” unit, which handles materials for customers such as Boeing and BMW, makes up a little over 12% of sales. Analysts’ estimates of enterprise value range from €1.2 billion to €4 billion: Deutsche Bank has €2.4 billion in its base case and more than €4 billion in a strategic scenario, Jefferies €3.6 billion, Bank of America €3.5 billion (Börsen-Zeitung). Chief executive Miguel López calls the spin-offs “Wertkristallisierung”, crystallising value.
The equity read. Three spreads, three gatekeepers. At Qiagen the gap is 3.2%: the threshold is low, and holding out costs money. At Evonik it is 12.9% to a price nobody has put in writing, and the yes that matters comes from a foundation with a political board, in a state whose government opposes the deal. TK Accelis has no offer at all. A parent with 51% decides whether a premium is ever paid, so the first trades on Wednesday set a price for the 49% that floats.
A measured approach:
Read each spread as a count of the yeses still missing. At 3.2%, Qiagen trades as if the deal will close. The only lever above €46.50 is a counterbid, and no one has confirmed one. At Evonik the market is pricing roughly a coin toss. What to watch: BaFin’s approval of the Qiagen offer document and the start of the acceptance period; BASF’s results on 28 October; Evonik’s results on 3 November and its investor day on 4 November.
Let TK Accelis set its own price before judging it. The range of analyst values is wider than three to one. What to watch: the first trades on 28 October and the first weeks after.
2. Signal vs. Noise: France Pays More Than Italy 📉
The Noise: France is in turmoil, and Europe’s spreads are blowing out.
The Alpha: France’s spread is widening, not Europe’s. Italy pays 122 basis points over Germany for ten years, Spain 70, France 170. The difference lines up with who holds the debt. Almost 55% of French government debt is held abroad. In Italy it was 35.9% in May, and this week Italian retail investors lent their government €16.6 billion. The money leaving France is going into Bunds.
The Filter: The French ten-year yield touched 5.14% on Thursday, the highest since July 2002 (Reuters), and closed the week at 5.04%. The ten-year Bund ended at 3.34%, its lowest since 31 August. The gap of about 170 basis points is the widest since the euro debt crisis (Trading Economics). Italy’s ten-year yield closed at 4.56%, 122 basis points over Bunds (ANSA). Spain’s was 4.06% on Thursday, 70 basis points over (QuiFinanza). France now pays 48 basis points more than Italy and about 100 more than Spain.
The trigger is the budget. On Friday Moody’s kept France at Aa3 with a negative outlook. The agency assumes a deficit-reducing budget for 2027 and expects debt above 120% of GDP that year. It puts this year’s deficit at about 5.4% of GDP (Dow Jones, via MarketScreener). The government targets 5% for 2027. Members of the National Assembly have removed some of the planned savings and added spending (Reuters). Fitch and S&P rate France A+, one notch lower, and S&P’s next review is on 27 November. The economy isn’t helping: France’s composite PMI fell to 48.4 in October, a contraction (S&P Global, via Newsquawk). Curfews in parts of Paris, Lille and Nice followed a weekend of riots (Reuters).
Who holds the debt. Almost 55% of French government debt was held abroad last year (Dow Jones, via MarketScreener). In Italy non-residents held 35.9% in May, according to the Bank of Italy (via Sky TG24). This week the Italian Treasury sold two bonds reserved for retail investors, BTP Valore and BTP Valore Insieme, and raised €16.6 billion from 560,029 orders (MEF, via QuiFinanza). A spread that foreign funds set can move faster than one that domestic savers absorb. Investors who sold French assets this week moved into Bunds and Treasuries (Reuters).
A measured approach:
Check the holder base before the yield. Among the four largest euro economies, France now pays the most for ten-year money, and most of its creditors can leave. What to watch: S&P on 27 November, the Assembly’s votes on the 2027 budget, and whether Italy’s spread stays near 120 basis points while France’s moves.
Filter Idea: Bunds over OATs, through the iShares eb.rexx Government Germany UCITS ETF (DE0006289465, Xetra: EXHA)
Thesis: France’s spread now depends on foreign buyers and on a budget that parliament is rewriting, and its next test comes on 27 November. Until then I’d hold euro government bonds on the German side. The fund holds 25 German federal securities with an effective duration of about five years and a yield to maturity of 3.16%, at a total expense ratio of 0.16% (iShares, 23 October).
What would prove me wrong: a 2027 budget that gets through the Assembly with the 5% deficit target intact, and S&P keeping A+ on 27 November. A five-year spread back below about 100 basis points would show that the market agrees.
Main risk: carry. At five years France yields 4.44% against 3.14% for Germany (Trading Economics), 1.3 points more a year. With a duration of about five, the five-year spread has to widen by roughly 26 basis points over twelve months before the German side does better. The second risk is the ECB. In 2022 it created its Transmission Protection Instrument against “unwarranted, disorderly market dynamics.” One of its criteria: a country in an excessive deficit procedure must not have been assessed as failing to take effective action (ECB). France has been in such a procedure since 2024, so the budget the Assembly is rewriting also decides whether the backstop is available. Any sign that the ECB would use it for France would work against this idea.
3. Signal vs. Noise: $117 Oil, and Two Central Banks Step Back 🛢️
The Noise: With oil at $117, the Fed and the ECB will have to keep raising rates.
The Alpha: The market went the other way. Futures cut the chance of a Fed hike on Wednesday to about 5%, the ECB is expected to hold on Thursday, and ten-year yields fell on both sides of the Atlantic. Investors are treating this oil shock as a growth problem first. For DACH earnings it is a cost problem first, and the companies that buy the most energy report this week.
The Filter: Brent settled at $116.72 on Friday, its highest in six months, after Houthi attacks on Saudi energy and transport infrastructure (Reuters; Yahoo Finance). Futures put the chance of a Fed hike on 28 October at about 5%, against 15% earlier in the week (Bloomberg data, via Yahoo Finance). On 14 October, after the inflation report, CME FedWatch had priced 41.5%. A week ago markets still firmly expected a hike on 9 December (Forbes). On Thursday the ten-year Treasury yield had its largest one-day fall in more than two years, and it ended the week at about 4.99%. The ECB, at a deposit rate of 2.50%, is widely expected to hold (Trading Economics). The euro area’s composite PMI fell to a four-month low of 51.9, and consumers’ inflation expectations rose to 3.1% (Newsquawk).
SAP put the risk in one sentence. Its first quarter above €10 billion of revenue came with a 26% rise in the current cloud backlog. Chief financial officer Dominik Asam said the fourth quarter would decide the year, with oil prices and US interest rates that “start to develop teeth” (Reuters).
The ECB that sets German yields next year will look different. Berlin has until Wednesday to nominate a successor for Isabel Schnabel, who moves to the IMF in early 2027. Chief economist Philip Lane’s term ends in May 2027, and Christine Lagarde has hinted that she may leave a few months before her term ends in October 2027 (Börsen-Zeitung; cash.ch).
The equity read. This is macro, so I’ll keep it short. Lower yields help valuations, and a higher oil price hurts margins. In the DACH region the large energy buyers report within a week of the two rate decisions: BASF on 28 October, Wacker Chemie on 29 October, Evonik and Lufthansa on 3 November, Lanxess on 5 November.
A measured approach:
Read this week’s results as oil reports. For BASF, Wacker, Evonik and Lufthansa the question is how much of the energy bill reaches the customer. What to watch: the Fed on 28 October at 19:00 CET, the ECB on 29 October, German GDP and inflation on 30 October.
🔎 Insider Radar
Under the EU’s market abuse rules, managers report their own trades within three business days. The filings show where management puts its own money. They don’t say why, and a purchase isn’t a forecast. This box reports; it doesn’t recommend.
Deutz. Supervisory board member Dietmar Voggenreiter bought shares for €50,400 at €10.08 on Thursday, and Simone Voggenreiter, a closely associated person, bought €49,675 at an average €9.935 the same day. In #040 I reported his purchase at €10.68 on 8 October. Deutz reports on 5 November.
Lenzing. The fibre maker closed a rights issue of about €300 million at €8.65 a share, 42.5% below the theoretical ex-rights price. Oberbank, closely associated with supervisory board member Martin Seiter, took up 1,344,177 new shares, about €11.6 million, as it had committed to do. Management board member Christian Skilich bought 1,710 shares at the same price. The indirect majority owners, B&C and Suzano, had committed about €157 million.
🔁 Last Week’s Watch List
⏳ Bayer. The shares closed the week at €43.98, down 1.1%. UBS keeps its buy rating with a €62 target. I found no ruling yet from the Missouri court on the class settlement. Bayer reports on 3 November.
⏳ Seeds and sprays. FMC reports its third quarter on 29 October and its first outlook for 2027 and 2028 on 30 October. BASF reports on 28 October.
⚠️ Telekom. Bloomberg reported on Thursday that SpaceX wants at least 80,000 US cell sites for its own network, the ground layer it lacked in #040. T-Mobile fell 7.7% on Friday, Telekom 3.2%, and part of the US move came after Frankfurt closed. Since #040, Telekom is up 2.6% and T-Mobile down 1.4%. SpaceX expects to close its 800 MHz purchase in the first half of 2027.
⏳ China avoid list. Volvo Cars fell 27% to a record low after a bigger-than-expected third-quarter loss, and Kering lost more than 10% on Gucci (Reuters). Porsche reports on 27 October, Mercedes on 28 October, Volkswagen on 29 October and BMW on 4 November. The list runs to 10 November.
Outro: Who Has to Say Yes
Every price in this issue waited on someone’s yes. Qiagen’s owners need to tender half the shares plus one. Evonik’s €24 needs a foundation whose board is mostly politicians. TK Accelis needs nobody, because the parent keeps control. France needs foreign investors to keep lending, while Italy found €16.6 billion at home in five days. And two central banks that looked ready to raise rates three weeks ago are now expected to wait.
The Takeaway: For each of your holdings, whose yes does the price depend on, and how sure are you that it will come?
Daniel Ruck Editor, The Ruck Filter
Filter Sources this week
Reuters (via WHBL) — EQT to acquire Qiagen, October 21, 2026
SEC — Qiagen announcement of the takeover offer (Crown NL BidCo, EQT XI), October 21, 2026
Analytica-World — Thermo Fisher and Qiagen amended terms, July 17, 2020; The Pharma Letter — Thermo Fisher offer lapses at 47.02%, August 2020
Börsen-Zeitung (dpa-AFX, Reuters) — EQT and KKR interest in Qiagen, October 21, 2026
Börse Express — Qiagen closing price, October 23, 2026
StockAnalysis — Qiagen prices, October 16–20, 2026; Telekom, T-Mobile US and Crown Castle prices, October 2026; Bayer closing price, October 23, 2026
dpa-AFX (via onvista) — BASF’s higher approach for Evonik, October 23, 2026; Frankfurt close, October 23, 2026
Der Aktionär — BASF and Evonik, first approach rejected, October 14, 2026
Evonik — ad hoc release on the 2026 outlook, June 26, 2026; analyst and investor fact sheet Q2 2026, August 4, 2026
ROIC.ai — Evonik shares outstanding, June 30, 2026
dpa-AFX (via extraETF) — Qiagen full-year 2025 results, February 4, 2026
Börse Express — NRW Landtag debate on BASF and Evonik, October 14, 2026
Börsen-Zeitung — TK Accelis valuation range and spin-off terms, October 21, 2026
Reuters (via Global Banking & Finance) — French yields and Moody’s review, October 23, 2026
MarketScreener (Dow Jones) — Moody’s keeps France at Aa3, October 23, 2026
Trading Economics — French and German government bond yields, spreads, ECB expectations, October 20–23, 2026
ANSA — BTP-Bund spread close, October 23, 2026
QuiFinanza — euro area yields and spreads, October 23, 2026; BTP Valore results, October 23, 2026
Sky TG24 (Bank of Italy data) — Italian debt held by non-residents, August 17, 2026
Reuters (via Yahoo Finance) — European shares, French unrest and PMIs, October 23, 2026
Newsquawk — European market wrap and flash PMIs, October 23, 2026
iShares — eb.rexx Government Germany UCITS ETF (DE), fund data as of October 23, 2026
European Central Bank — Transmission Protection Instrument and its eligibility criteria, July 21, 2022
Yahoo Finance — Wall Street close, Fed expectations and oil, October 23, 2026
Reuters (via Engineering News) — Brent and attacks on Saudi sites, October 20, 2026
247 Wall St — CME FedWatch after the CPI, October 15, 2026
Forbes — October FOMC preview, October 19, 2026
Reuters (via WSAU) — SAP third-quarter results, October 21, 2026
Börsen-Zeitung — Germany’s claim to the ECB board seat, October 9, 2026; cash.ch — ECB nomination deadline, October 9, 2026
boerse.de (dpa-AFX) — calendar to November 6, 2026
EQS-DD — Deutz (Dietmar and Simone Voggenreiter), October 23, 2026; Lenzing (Oberbank AG, Christian Skilich), October 23, 2026
Lenzing AG — rights issue terms, October 1, 2026
goldesel — UBS on Bayer, October 2026
Yahoo Finance (citing Bloomberg) — SpaceX talks with Crown Castle, October 23, 2026
SpaceX — third-quarter 2026 results
Reuters (via Yahoo Finance) — Volvo Cars and Kering, October 23, 2026
Disclaimer: The Ruck Filter is for informational purposes only and does not constitute financial, investment, or tax advice. The information provided is based on data available at the time of writing and is subject to change. Investing in financial markets involves risks, including the potential loss of principal. Every reader is solely responsible for their own trading and investment decisions. Please conduct your own due diligence or consult with a licensed professional before making any financial commitments. Companies with potential conflicts of interest are excluded from coverage as a matter of editorial policy.